Medications
What each medicine is approved for, in a named country, according to the regulator there. Approvals differ between countries. This is background reading, not advice: nothing here tells you what to take, start or stop — only your clinician can do that.
Clinically reviewed profiles
No plain-language profile has been published yet. A profile only appears once a named clinician has checked it against the regulator's own document, so until then use the official sources below.
Official medication sources
Verified product name, ingredient, country, regulator and a direct link to the official record. These entries are source links only — they carry no summary of what the medicine does, and no clinician has reviewed them.
35 of 35 entries shown
Source link only
Ampyra
dalfampridine
- Country or region
- United States
- Regulator
- FDA
- Given as
- Oral
- Type
- Symptom management
Ampyra — FDA prescribing information · document version 2021-11 · checked 2026-09-06
Source link only
Aubagio
teriflunomide
- Country or region
- European Union
- Regulator
- EMA / European Commission
- Given as
- Oral
- Type
- Disease-modifying therapy
Aubagio — EMA medicine record · document version 2025-12-09 · checked 2026-09-06
Source link only
Aubagio
teriflunomide
- Country or region
- United States
- Regulator
- FDA
- Given as
- Oral
- Type
- Disease-modifying therapy
Aubagio — FDA prescribing information · document version 2026-02 · checked 2026-09-06
Source link only
Avonex
interferon beta-1a
- Country or region
- United States
- Regulator
- FDA
- Given as
- Intramuscular injection
- Type
- Disease-modifying therapy
Avonex — FDA prescribing information · document version 2023-07 · checked 2026-09-06
Source link only
Bafiertam
monomethyl fumarate
- Country or region
- United States
- Regulator
- FDA
- Given as
- Oral
- Type
- Disease-modifying therapy
Bafiertam — FDA prescribing information · document version 2024-09 · checked 2026-09-06
Source link only
Betaseron
interferon beta-1b
- Country or region
- United States
- Regulator
- FDA
- Given as
- Subcutaneous injection
- Type
- Disease-modifying therapy
Betaseron — FDA prescribing information · document version 2023-07 · checked 2026-09-06
Source link only
Briumvi
ublituximab-xiiy
- Country or region
- United States
- Regulator
- FDA
- Given as
- Intravenous infusion
- Type
- Disease-modifying therapy
Briumvi — FDA prescribing information · document version 2026-01 · checked 2026-09-06
Source link only
Cenrifki
tolebrutinib
- Country or region
- Australia
- Regulator
- TGA
- Given as
- Not confirmed
- Type
- Disease-modifying therapy
Cenrifki — Australian prescription medicine decision summary · checked 2026-09-06
Source link only
Cenrifki
tolebrutinib
- Country or region
- European Union
- Regulator
- EMA / European Commission
- Given as
- Oral
- Type
- Disease-modifying therapy
Cenrifki — EMA product information · document version 2026-08-21 · checked 2026-09-06
Source link only
Copaxone
glatiramer acetate
- Country or region
- United States
- Regulator
- FDA
- Given as
- Subcutaneous injection
- Type
- Disease-modifying therapy
Copaxone — FDA prescribing information · document version 2026-06 · checked 2026-09-06
Source link only
Gilenya
fingolimod
- Country or region
- United States
- Regulator
- FDA
- Given as
- Oral
- Type
- Disease-modifying therapy
Gilenya — FDA prescribing information · document version 2025-08 · checked 2026-09-06
Source link only
Gilenya
fingolimod
- Country or region
- European Union
- Regulator
- EMA / European Commission
- Given as
- Oral
- Type
- Disease-modifying therapy
Gilenya — EMA product information · document version 2026-07-30 · checked 2026-09-06
Source link only
Glatopa
glatiramer acetate
- Country or region
- United States
- Regulator
- FDA
- Given as
- Subcutaneous injection
- Type
- Disease-modifying therapy
Glatopa — submitted prescribing information · document version 2026-07 · checked 2026-09-06
Source link only
Kesimpta
ofatumumab
- Country or region
- United States
- Regulator
- FDA
- Given as
- Subcutaneous injection
- Type
- Disease-modifying therapy
Kesimpta — FDA prescribing information · document version 2026-04 · checked 2026-09-06
Source link only
Kesimpta
ofatumumab
- Country or region
- European Union
- Regulator
- EMA / European Commission
- Given as
- Subcutaneous injection
- Type
- Disease-modifying therapy
Kesimpta — EMA product information · document version 2026-08-20 · checked 2026-09-06
Source link only
Lemtrada
alemtuzumab
- Country or region
- United States
- Regulator
- FDA
- Given as
- Intravenous infusion
- Type
- Disease-modifying therapy
Lemtrada — FDA prescribing information · document version 2024-05 · checked 2026-09-06
Source link only
Mavenclad
cladribine
- Country or region
- United States
- Regulator
- FDA
- Given as
- Oral
- Type
- Disease-modifying therapy
Mavenclad — FDA prescribing information · document version 2026-05 · checked 2026-09-06
Source link only
Mavenclad
cladribine
- Country or region
- European Union
- Regulator
- EMA / European Commission
- Given as
- Oral
- Type
- Disease-modifying therapy
Mavenclad — EMA medicine record · document version 2026-01-13 · checked 2026-09-06
Source link only
Mayzent
siponimod
- Country or region
- United States
- Regulator
- FDA
- Given as
- Oral
- Type
- Disease-modifying therapy
Mayzent — FDA prescribing information · document version 2026-06 · checked 2026-09-06
Source link only
Mayzent
siponimod
- Country or region
- European Union
- Regulator
- EMA / European Commission
- Given as
- Oral
- Type
- Disease-modifying therapy
Mayzent — EMA product information · document version 2026-07-30 · checked 2026-09-06
Source link only
Ocrevus
ocrelizumab
- Country or region
- European Union
- Regulator
- EMA / European Commission
- Given as
- Intravenous infusion
- Type
- Disease-modifying therapy
Ocrevus — EMA product information · document version 2026-08-20 · checked 2026-09-06
Source link only
Ocrevus
ocrelizumab
- Country or region
- European Union
- Regulator
- EMA / European Commission
- Given as
- Subcutaneous injection by a healthcare professional
- Type
- Disease-modifying therapy
Ocrevus — EMA product information · document version 2026-08-20 · checked 2026-09-06
Source link only
Ocrevus
ocrelizumab
- Country or region
- United States
- Regulator
- FDA
- Given as
- Intravenous infusion
- Type
- Disease-modifying therapy
Ocrevus — FDA prescribing information · document version 2026-05 · checked 2026-09-06
Source link only
Ocrevus Zunovo
ocrelizumab and hyaluronidase-ocsq
- Country or region
- United States
- Regulator
- FDA
- Given as
- Subcutaneous injection by a healthcare professional
- Type
- Disease-modifying therapy
Ocrevus Zunovo — FDA prescribing information · document version 2025-08 · checked 2026-09-06
Source link only
Ozobax DS
baclofen
- Country or region
- United States
- Regulator
- FDA
- Given as
- Oral
- Type
- Symptom management
Ozobax DS — FDA prescribing information · document version 2023-09 · checked 2026-09-06
Source link only
Plegridy
peginterferon beta-1a
- Country or region
- United States
- Regulator
- FDA
- Given as
- Subcutaneous or intramuscular injection
- Type
- Disease-modifying therapy
Plegridy — FDA prescribing information · document version 2023-07 · checked 2026-09-06
Source link only
Ponvory
ponesimod
- Country or region
- United States
- Regulator
- FDA
- Given as
- Oral
- Type
- Disease-modifying therapy
Ponvory — FDA prescribing information · document version 2024-06 · checked 2026-09-06
Source link only
Rebif
interferon beta-1a
- Country or region
- United States
- Regulator
- FDA
- Given as
- Subcutaneous injection
- Type
- Disease-modifying therapy
Rebif — FDA prescribing information · document version 2023-07 · checked 2026-09-06
Source link only
Tascenso ODT
fingolimod
- Country or region
- United States
- Regulator
- FDA
- Given as
- Oral
- Type
- Disease-modifying therapy
Tascenso ODT — FDA prescribing information · document version 2026-06 · checked 2026-09-06
Source link only
Tecfidera
dimethyl fumarate
- Country or region
- European Union
- Regulator
- EMA / European Commission
- Given as
- Oral
- Type
- Disease-modifying therapy
Tecfidera — EMA product information · checked 2026-09-06
Source link only
Tecfidera
dimethyl fumarate
- Country or region
- United States
- Regulator
- FDA
- Given as
- Oral
- Type
- Disease-modifying therapy
Tecfidera — FDA prescribing information · document version 2024-03 · checked 2026-09-06
Source link only
Tyruko
natalizumab-sztn
- Country or region
- United States
- Regulator
- FDA
- Given as
- Intravenous infusion
- Type
- Disease-modifying therapy
Tyruko — FDA prescribing information · document version 2025-10 · checked 2026-09-06
Source link only
Tysabri
natalizumab
- Country or region
- United States
- Regulator
- FDA
- Given as
- Intravenous infusion
- Type
- Disease-modifying therapy
Tysabri — FDA prescribing information · document version 2025-03 · checked 2026-09-06
Source link only
Vumerity
diroximel fumarate
- Country or region
- United States
- Regulator
- FDA
- Given as
- Oral
- Type
- Disease-modifying therapy
Vumerity — FDA prescribing information · document version 2024-09 · checked 2026-09-06
Source link only
Zeposia
ozanimod
- Country or region
- United States
- Regulator
- FDA
- Given as
- Oral
- Type
- Disease-modifying therapy
Zeposia — FDA prescribing information · document version 2024-08 · checked 2026-09-06